Eurofins expands global technology portfolio and geographic reach with Lancaster Laboratories

Lisa Bamford, Eurofins Lancaster Laboratories, USA

With the later acquisition of top US testing firm, Lancaster Laboratories, the Eurofins Group takes a leadership position in North America in two strategic markets: Pharm/ Biopharm product testing and Environmental testing.

Founded in 1961, Eurofins Lancaster Laboratories brings a significant North American presence with an unmatched breadth of bio/pharmaceutical, environmental and scientific staffing capabilities as well as a sterling track record for regulatory compliance, cost effectiveness and achievement of timelines for customers.

Eurofins Lancaster Labs’ FDA, EMA and PMDA cGMPcompliant Bio/Pharma divisions enable 800 global life sciences customers - including 19 of the top 20 bio/ pharmaceutical companies - to advance development candidates and release marketed products through a complete set of services for drug substance, drug product, manufacturing and starting materials testing.

With 1,200 employees and state-of-the-art facilities in the USA and Ireland, Eurofins Lancaster Laboratories has built a strong customer following by listening to project needs and delivering solutions through five flexible service models, which all provide a seamless service experience throughout the outsourcing process:

• Fee For Service: Most commonly used in the industry, this model allows Eurofins Lancaster Labs’ staff to provide a broad range of pharmaceutical and biopharmaceutical product testing on a project-by-project basis, utilizing customized price quotes for each project delivered.
• Managed Hours: This approach allows in-house staff to provide a broad range of pharmaceutical and biopharmaceutical product testing on a project-by-project basis with a simplified quote and payment process based on the number of hours used. This meets the needs of clients who have a high volume of repeat (standardized) testing needs.
• Full Time Equivalent: This provides clients with dedicated full-time employees, working within Eurofins Lancaster Laboratories’ facilities and using its infrastructure, equipment and consumables.
• Asset/Operation Ownership: Eurofins Lancaster Laboratories assumes full operational responsibility on the client site. This model can also include acquisition of the client’s facility and/or equipment. While this model may only apply to a small percentage of companies in the industry, some firms are seeking ways to fully outsource non-core activities and divest of the associated assets.
• Professional Scientific Staffing: This award-winning model places Lancaster Laboratories’ full-time scientists and technical support personnel at the client’s facility to provide a non-permanent, long term and cost-effective way to meet staffing needs while maintaining the same services, expertise and cGMP compliance available at the Lancaster Laboratories’ facilities.

Among the most innovative and quality oriented international players in the industry, Eurofins Pharma Services with Lancaster Laboratories is ideally positioned to support customers’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

For more information on Eurofins Lancaster Laboratories’ capabilities, visit www.eurofins.com/lancasterlabs .

Contact: GMP_US@eurofins.com